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W

HEN H IPPOCRATES ADVISED PHYSICIANS TO
never give a deadly drug, he assumed they
would know for sure that the medicines
they prescribed were safe. Today, criminals
and unscrupulous manufacturers have permeated the
global pharmaceutical market, calling into question this
basic assumption of clinical practice. Between November
2012 and March 2013, an injectable drug compounded
under unhygienic conditions at the New England Compounding Pharmacy was linked to more than 700 illnesses
and 50 deaths.1 In poor countries, where drug regulatory
oversight is weaker, the problem is worse, but blends with
the background noise of high mortality and strained health
systems. Only in rare cases, as when 120 Pakistanis died
after taking a carelessly made batch of isosorbide mononitrate, do people in low- and middle-income countries learn
of their vulnerability.2
The pharmaceutical trade is transnational, lucrative, and
extensive; the United Nations Office on Drugs and Crime
estimates the value of the illegal antimalarial drug market
in west Africa alone exceeds $400 million.3 These products
pose immense dangers. Falsified and substandard drugs may
contain no active pharmaceutical ingredient or contain the
active ingredient at subtherapeutic doses. Poor-quality antimicrobial drugs are a major problem in Southeast Asia and
sub-Saharan Africa,4,5 where they contribute to drug resistance, reducing a drug’s effectiveness. Society must bear the
cost of developing alternate therapies. Poor-quality products increase health care costs, while causing patients to lose
confidence in the health system.
In a report released recently, an Institute of Medicine expert committee examined the causes of, and solutions to,
the problem of falsified and substandard drugs in the United
States and globally.6

A Common Language
At the heart of the problem is a lack of a common language. Some emerging manufacturing nations and civil society groups object to using the broad descriptor counterfeit for all poor-quality drugs. In a narrow sense, counterfeit
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products are only those that infringe on a registered trademark. Stakeholders concerned with access to generic medicines fear that action against counterfeit drugs would mean
stricter enforcement of intellectual property rights, thereby
reducing the availability of inexpensive generics.
To avoid confusion, the term counterfeit should be used
only to describe a trademark infringement. Medicines posing a public health concern include 2 overlapping categories. A falsified drug misrepresents the product’s identity,
source, or both. A substandard drug fails to meet national
specifications in accepted pharmacopoeia or the manufacturer’s dossier. This language frames falsified and substandard medicines exclusively as a public health problem. Consistent use of these terms would facilitate clear communication
among regulators, police, and industry. A common language would allow for more accurate measurement of the
scope and trends at the national and global levels.
Pharmacovigilance
There are no reliable estimates of the global burden of falsified and substandard medicines. The World Health Organization has a promising pilot approach to train regulators for drug quality surveillance in 10 developing countries,
using rapid alert forms to identify dangerous products and
link incidents across different countries. Governments should
establish or strengthen systems to detect and monitor substandard and falsified medicines, integrating pharmacovigilance into routine national surveillance. Quality surveillance would improve understanding of the types of products
compromised and the extent of the trade.
Track and Trace
A porous global supply chain allows good medicines to be
diverted to the illicit market and poor-quality medicines to
enter the legal one. Securing the medicines’ chain of custody
would protect the drug supply. Track and trace systems empower stakeholders to know a drug’s location and authenticity throughout the distribution chain. A federal track and
trace system would enable companies to follow a uniform standard without state variations. Therefore, Congress should authorize and fund the Food and Drug Administration (FDA)
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to establish a mandatory track and trace system. In the interim, the FDA should convene stakeholders to promote voluntary track and trace for all supply chain actors. FDA action would protect the US consumer, while building
momentum for tighter medicine controls internationally.
Wholesale Licensing
Secondary wholesalers and state standards vary widely. States
license wholesalers, with standards varying widely. Unscrupulous firms seek out states with weak oversight. Because
the wholesale market is national, weaknesses in one state’s
system threaten the others. To rectify this problem, states
should grant licenses only to wholesalers meeting the National Association of Boards of Pharmacy accreditation standards. The FDA could promote openness in the licensing
process by creating a public database to share information
on suspended and revoked wholesale licenses. Tight accreditation and transparent information sharing would help
thwart irresponsible wholesalers.
Quality Manufacturing
Drug production depends on good manufacturing practices and quality control. Small- and medium-sized drug companies in developing countries lack the infrastructure, equipment, and staff necessary to meet international standards.
These firms do not operate on a scale that allows them to
recover the costs of running a modern factory, and they have
few avenues to raise capital from national banks. The World
Bank’s International Finance Group and the US government’s Overseas Private Investment Corporation should invest in pharmaceutical manufacturing in developing countries. Companies that avail themselves of loans can raise their
standards, thus providing inexpensive, quality medicines in
a market starved for them.
Drug Retail
The private sector also has a role in improving drug retail
in developing countries, where the poor often have no choice
but to purchase drugs from unlicensed shops or open-air
markets. These markets violate many basic principles of responsible pharmacy practice: tablets are sold loose, blister
packs cut apart, and secure storage is rare. Shopkeepers have
no training in the proper handling or buying of medicines.
Inasmuch as development finance organizations can help
good-faith manufacturers, governments can use training,
franchising, and accreditation schemes to create better drug
retail. National pharmacy councils can improve workforce
efficiency by assigning some pharmacy tasks to technicians, a process known as task shifting. Vocational training
in dispensing medicines, combined with incentives to re-
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tain trained staff in rural areas and slums, would improve
medicines’ retail in the poorest countries.
International Code of Practice
National regulatory authorities have the final responsibility for a country’s drug supply: preventing falsified and substandard drugs from entering the market, detecting them
when they do, and punishing unscrupulous actors. However, no country acting alone can protect its inhabitants from
falsified and substandard medicines.
The World Health Organization has the constitutional authority to promulgate an international code of practice, a
type of voluntary soft law, pertaining to falsified and substandard medicines. This code would catalyze stakeholder
action and coordinate regulatory, customs, and law enforcement agencies. The World Health Assembly, in partnership with United Nations Office on Drugs and Crime and
the World Customs Organization, should develop the code
using an open and inclusive process. The code would offer
guidance on standard terminology, surveillance, regulation, and law enforcement. It would set clear targets, monitor results, and mobilize resources and technical assistance
for low- and middle-income countries. Most importantly,
the code would promote international cooperation and multisector action against the criminal syndicates that poison
the world’s medicine supply.
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